



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Clinical Letter

## Guillain-Barré Syndrome After COVID-19 Vaccination in an Adolescent

Emily Malamud, BA<sup>a,\*</sup>, Scott I. Otallah, MD<sup>a</sup>, James B. Caress, MD<sup>b</sup>, Daniel J. Lapid, MD<sup>a</sup><sup>a</sup> Division of Pediatric Neurology, Department of Neurology, Wake Forest University/Brenner Children's Hospital, Winston-Salem, North Carolina<sup>b</sup> Division of Neuromuscular Disease, Department of Neurology, Wake Forest University, Winston-Salem, North Carolina

## ARTICLE INFO

## Article history:

Received 19 August 2021

Accepted 4 October 2021

Available online 8 October 2021

## Keywords:

Guillain-Barre syndrome

COVID-19 vaccine

SARS-CoV-2 virus

Pfizer

Guillain-Barré syndrome (GBS) has been associated with SARS-CoV-2 infection in adults and children,<sup>1</sup> and it has been noted as an adverse effect with the Janssen COVID-19 vaccine in adults.<sup>2</sup> There have been no cases reported of children developing GBS after COVID-19 vaccination, to our knowledge.

We describe a child who developed GBS within one month of the administration of the second dose of the Pfizer-BioNTech COVID-19 vaccine. Our patient is a 14-year-old male who received the second dose of the Pfizer-BioNTech COVID-19 vaccine on June 11, 2021. He had previously never been diagnosed with COVID-19. On July 3, he experienced left lower extremity swelling up to the knee after a probable bee sting to the bottom of his left second toe, which resolved within two weeks without treatment. On July 11, he reported subjective facial weakness and subjective tongue swelling, for which he received oral prednisone at an urgent care facility. Owing to increasing facial weakness, he was evaluated in the emergency department on July 14, and he underwent diagnostic testing for common causes of facial palsy. No other weakness was

reported on examination at that time. He was admitted on July 19 for progressive facial and limb weakness with areflexia. COVID-19 antigen testing was negative upon admission. On examination, he had significant difficulty ambulating, bilateral facial weakness worse on the left, and 4+/5 strength throughout the left hemibody but preserved strength on the right side. Over the next few days, he became quadriparetic and was unable to ambulate independently. Breathing was never impaired.

This child's diagnosis of GBS was confirmed through clinical presentation; cerebrospinal fluid showing 4 white blood cells and 165 mg/dL protein, indicating cytoalbuminocytologic dissociation; and electrodiagnostic studies demonstrating a severe, generalized polyradiculoneuropathy, with demyelinating features indicating the acute inflammatory demyelinating polyradiculoneuropathy variant of GBS. Although this patient did not have any sensory losses, both acute inflammatory demyelinating polyradiculoneuropathy and the acute motor axonal neuropathy variants can cause pure motor symptoms.<sup>3</sup> Additional cerebrospinal fluid and serum testing excluded alternative etiologies, including negative Lyme antibodies, Lyme polymerase chain reaction, and ganglioside antibodies.

Our patient was treated with 2 g/kg IVIg over 3 days. Beginning on the third day of his IVIg course, he demonstrated marked improvement in his facial and limb weakness. Before discharge, he was able to ambulate with assistance and went home with outpatient physical therapy seven days after admission. At his follow-up appointment in mid-August, he reported full resolution

Conflict of interest: The authors have no conflicts of interest to disclose.

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Patient consent: Patient and parents have provided informed consent for the publication of the case.

\* Communications should be addressed to: Ms. Malamud; Division of Pediatric Neurology; Department of Neurology; Wake Forest University/Brenner Children's Hospital; Medical Center Boulevard, JT9; Winston-Salem, NC 27157.

E-mail address: [emalamud@wakehealth.edu](mailto:emalamud@wakehealth.edu) (E. Malamud).

of his neurologic symptoms, and no neurologic abnormalities were noted on physical examination.

We are unaware of other pediatric cases of GBS reported in association with a COVID-19 vaccination. Although our patient experienced a probable bee sting in the time after his vaccination, we find it unlikely that this was a direct cause of our patient's GBS given the scarcity of case reports on this association<sup>4</sup> and the quick resolution of localized symptoms. Following the 1976 National Influenza Immunization Program, which was associated with an increased risk of GBS up to 10 weeks after administration, there has been intense scrutiny of subsequent influenza vaccines. Results from analyses of subsequent vaccines have been uneven but are associated with at least a slight increased risk of GBS after many vaccinations in both children<sup>5</sup> and adults,<sup>6</sup> suggesting an etiological linkage. COVID-19 vaccines could trigger GBS via molecular mimicry or via a nonspecific immune response to the vaccine. The incidence of GBS in children is 0.34 to 1.34 cases per 100,000 person,<sup>7</sup> so it is also possible that this case occurred coincidentally with the vaccine.

The onset of GBS within six weeks of vaccination suggests a possible causative association, but large-scale epidemiologic

studies are required to determine if COVID-19 vaccination increases the risk of GBS in this population.

## References

1. Abu-Rumeileh S, Abdelhak A, Foschi M, Tumani H, Otto M. Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. *J Neurol*. 2021;268:1133–1170.
2. Janssen COVID-19 vaccine EUA fact sheet for healthcare providers. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUUpdate.html>. Accessed August 13, 2021.
3. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barre syndrome. *Lancet*. 2016;388:717–727.
4. Saini AG, Sankhyan N, Suthar R, Singhi P. Acute axonal polyneuropathy following honey-bee sting: a case report. *J Child Neurol*. 2014;29:674–676.
5. Wise ME, Viray M, Sejvar JJ, et al. Guillain-Barre syndrome during the 2009–2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. *Am J Epidemiol*. 2012;175:1110–1119.
6. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. *Am J Epidemiol*. 1979;110:105–123.
7. Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. *Neuroepidemiology*. 2011;36:123–133.